Get the latest news, insights, and market updates on XERS (Xeris Biopharma Holdings, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Nov 6, 2025 - $XERS
Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3
Xeris Biopharma (XERS) delivered earnings and revenue surprises of -100.00% and +0.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 6, 2025 - $XERS
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
CHICAGO, November 06, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025. Nov 6, 2025 - $XERS
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript
Need a quote from a Motley Fool analyst? The strength of our year-to-date results gives us the confidence to raise the lower end of our full-year total revenue guidance. This momentum reflects a continuing expansion of new patients and prescribers. Nov 6, 2025 - $XERS
How Phase 3 XP-8121 Progress at Xeris Biopharma Holdings (XERS) Has Changed Its Investment Story
In recent days, Xeris Biopharma Holdings gained recognition in the biotechnology sector with strong revenue growth driven by commercial-stage therapies such as Gvoke, Keveyis, and Recorlev, alongside continued investment in the Phase 3 development of XP-8121 for hypothyroidism. This momentum has sparked increased analyst and investor interest, reflecting optimism around the company’s expanding product pipeline and future market potential. We'll explore how the advancement of XP-8121 in... Oct 28, 2025 - $XERS
Xeris Biopharma (XERS): Evaluating Valuation as Revenue Growth and Pipeline Advances Spark Renewed Optimism
Recent updates on Xeris Biopharma Holdings (XERS) highlight the company’s momentum in revenue growth, driven largely by strong performance of its approved products and major investments in research and development. Investors are particularly watching advancements in the pipeline. See our latest analysis for Xeris Biopharma Holdings. With optimism building around its breakthrough drug developments, Xeris Biopharma’s 169% share price return so far this year has captured the spotlight. Long-term... Oct 28, 2025 - $XERS
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
CHICAGO, October 23, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Thursday, November 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Oct 23, 2025 - $XERS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple